Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

References

  1. Khattar P, Pichardo J, Jungbluth A, et al. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies. Blood. 2017;130(Suppl_1):2755.  
  2. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 2008;19(3-4):263-276.
  3. Bolkun L, Grubczak K, Schneider G, et al. Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia. J Cancer. 2016;7(14):1979-1983.
  4. Sanchez E, Tanenbaum EJ, Patil S, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018;18(4):319-329.
  5. Udd KA, Rassenti LZ, David ME, et al. Plasma B-Cell maturation antigen levels are elevated and correlate with disease activity in patients with chronic lymphocytic leukemia. Blood. 2015;126(23):2931.
  6. Hagner PR, Waldman M, Gray FD, et al. Targeting B-cell maturation antigen (BCMA) with CC-93269, a 2+1 T Cell engager, elicits significant apoptosis in diffuse Large B-cell lymphoma preclinical models. Blood. 2019;134(Suppl_1):1580.
  7. Bluhm J, Kieback E, Marino SF, et al. CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin's lymphoma and multiple myeloma. Mol Ther. 2018;26(8):1906-1920.
  8. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109(2):729-739.
  9. Friedman KM, Garrett TE, Evans JW, et al. Effective targeting of multiple B-Cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018;29(5):585-601.
  10. Laâbi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992;11(11):3897-3904.

Advertisement

Advertisement

Advertisement

Advertisement